Literature DB >> 10234158

Selective proteasome inhibitors: modulators of antigen presentation?

.   

Abstract

The proteasome is the main nonlysosomal endoprotease in the cytoplasm and nucleus of all eukaryotic cells. It is responsible for the generation of most antigenic peptides as ligands for major histocompatibility complex (MHC) class I proteins. The proteasome hence qualifies as a target for modifying or silencing antigen processing and presentation to cytotoxic T cells, which are important players in transplant rejection and autoimmune disease. The authors summarize recent progress in the understanding of antigen processing by the proteasome and discuss the potential of novel and selective proteasome inhibitors as drugs for suppressing or modifying the cytotoxic immune response.

Entities:  

Year:  1999        PMID: 10234158     DOI: 10.1016/s1359-6446(98)01292-6

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  10 in total

1.  The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses.

Authors:  K Schwarz; R de Giuli; G Schmidtke; S Kostka; M van den Broek; K B Kim; C M Crews; R Kraft; M Groettrup
Journal:  J Immunol       Date:  2000-06-15       Impact factor: 5.422

2.  Dextran sulfate sodium-induced colitis is associated with enhanced low molecular mass polypeptide 2 (LMP2) expression and is attenuated in LMP2 knockout mice.

Authors:  Leo R Fitzpatrick; Vineeta Khare; Jeffrey S Small; Walter A Koltun
Journal:  Dig Dis Sci       Date:  2006-07       Impact factor: 3.199

3.  Selective inhibitor of proteasome's caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like sites.

Authors:  Matthew Britton; Marcella M Lucas; Sondra L Downey; Michael Screen; Alexandre A Pletnev; Martijn Verdoes; Robert A Tokhunts; Omar Amir; Ayrton L Goddard; Philip M Pelphrey; Dennis L Wright; Herman S Overkleeft; Alexei F Kisselev
Journal:  Chem Biol       Date:  2009-12-24

4.  Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction.

Authors:  Jonathan D Finn; Daniel Hui; Harre D Downey; Danielle Dunn; Gary C Pien; Federico Mingozzi; Shangzhen Zhou; Katherine A High
Journal:  Mol Ther       Date:  2009-11-10       Impact factor: 11.454

5.  Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib.

Authors:  Anne C Mirabella; Alexandre A Pletnev; Sondra L Downey; Bogdan I Florea; Tamer B Shabaneh; Matthew Britton; Martijn Verdoes; Dmitri V Filippov; Herman S Overkleeft; Alexei F Kisselev
Journal:  Chem Biol       Date:  2011-05-27

Review 6.  Proteasome inhibition: a new anti-inflammatory strategy.

Authors:  Peter J Elliott; Thomas Matthias Zollner; Wolf-Henning Boehncke
Journal:  J Mol Med (Berl)       Date:  2003-03-26       Impact factor: 4.599

Review 7.  Proteasome inhibition: a new strategy in cancer treatment.

Authors:  J Adams; V J Palombella; P J Elliott
Journal:  Invest New Drugs       Date:  2000-05       Impact factor: 3.850

8.  Bivalency as a principle for proteasome inhibition.

Authors:  G Loidl; M Groll; H J Musiol; R Huber; L Moroder
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

9.  Novel Pharmacological Approaches for Inflammatory Bowel Disease: Targeting Key Intracellular Pathways and the IL-23/IL-17 Axis.

Authors:  Leo R Fitzpatrick
Journal:  Int J Inflam       Date:  2012-03-15

Review 10.  Role of proteasomes in disease.

Authors:  Burkhardt Dahlmann
Journal:  BMC Biochem       Date:  2007-11-22       Impact factor: 4.059

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.